People · Operator
Named in public records as an officer, director or promoter · active 2010–2015 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | — | Biotechnology | Series D+ | $614.0M | $8.0B | 2015 |
| Aria Diagnostics, Inc. | — | Biotechnology | Series C | $65.2M | $2.2B | 2010 |
| Sequenta, Inc. | — | Other | Series B | $44.9M | $332.3M | 2010 |
John Stuelpnagel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Stuelpnagel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bryan Roberts | 1 | 18 |
| Rowan Chapman | 1 | 7 |
| Bryan E. Roberts | 1 | 6 |
| Kim Kamdar | 1 | 6 |
| Lee Huntsman | 1 | 5 |
| Bill Ericson | 1 | 5 |
| Chad Robins | 1 | 5 |
| Jim Tananbaum | 1 | 4 |
| Arnold Levine | 1 | 4 |
| Peter Neupert | 1 | 4 |
| Malek Faham | 1 | 3 |
| Thomas Willis | 1 | 3 |
| Chad Cohen | 1 | 2 |
| Kenneth Song | 1 | 2 |
| Jacob Goldfield | 1 | 2 |
| Michael E. Mitchell | 1 | 2 |
| Tom Willis | 1 | 2 |
| Chris Carlson | 1 | 2 |
| Harlan Robins | 1 | 2 |
| Craig Weissman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.